The anticancer drug TRK-950, an antibody against a target discovered in-house, will be tested in Phase I starting in the US and France from March 2017. Activity of the monoclonal antibody was confirmed in 16 cancer types such as lung, breast, and pancreatic cancer This is the first time that the company will handle clinical trials for anticancer drugs.

Toray news release, February 28, 2017